TreatSMA advocates for universal newborn screening for SMA

This week we submitted our comments to the NHS consultation on newborn screening for spinal muscular atrophy. We were shocked to learn that NHS argues against introducing this procedure, and we strongly objected to their views.

Universal newborn screening would allow parents to learn about the disease early and get prepared. It would allow the professionals to introduce best proactive care very early in the disease course. Finally, it would allow doctors to initiate pharmaceutical treatment or offer participation in clinical trials of new, upcoming medications, and thus possibly prevent the disease symptoms from ever appearing.

This would all be possible before the child’s neurones and muscles underwent irreversible deterioration.

In its official review, NHS argued that SMA epidemilogy is uncertain, that the genetic tests do not detect 100% of cases, and that “there is no approved treatment for SMA”. They concluded that universal screening for SMA should not be introduced in the UK.

We have challenged this view. In our response, which will is to be published on the NHS consultation website soon, we stressed that SMA population numbers are fairly well know; that the existing genetic testing methods are highly specific and reliable; and that a pharmacological treatment of SMA does exist and is effective.

We do not yet know how much impact we will make, but we will not stop in our efforts.

Latest Posts

  • Calling on all the community to ACT NOW to avoid losing treatments!

    Calling on all the community to ACT NOW to avoid losing treatments!

    Currently, there are two approved treatments for SMA: risdiplam and nusinersen. These treatments were initially approved temporarily under Managed Access Agreements while the NHS and NICE gathered data to assess their cost-effectiveness. Now, as these agreements come to an end, both treatments face a crucial review.

    Read more

  • NICE’s upcoming Multi Technology Assessment for Spinraza and Risdiplam

    NICE’s upcoming Multi Technology Assessment for Spinraza and Risdiplam

    SMA UK are proud to join together with Treat SMA and MDUK to bring you this webinar about NICE’s upcoming Multi Technology Assessment for Spinraza and Risdiplam. 2024 sees the end of the managed access agreements (MAAs) for the two treatments. An expert committee will gather to assess the new clinical and real-world evidence, along…

    Read more

  • Let the battle begin

    Let the battle begin

    This year the Managed Access Agreement for Spinraza and Risdiplam expires. The MAA was put in place five years ago so the pharmaceutical companies could gather more evidence to resubmit to NICE for approval on the NHS with Biogen extending their MAA by a year.

    Read more